kallikrein

Kallikrein 能够在血浆和组织中形成激肽释放酶激肽系统（KKS)，分别产生缓激肽和激肽肽。

Aprotinin (Traskolan) 是一种广谱丝氨酸蛋白酶 (BPTI) 抑制剂，可抑制多种不同酯酶和蛋白酶的活性。Aprotinin 是一种抗纤溶剂，用于减少复杂手术中的出血。

LSP-249是血浆 kallikrein 的抑制剂，用于血管性水肿的研究，EC50值小于 100 nM。

KKI-5 acetate(97145-43-2 free base) 是一种丝氨酸蛋白酶抑制剂，可抑制激肽释放酶和纤溶酶。 KKI 5 可能表现出抗癌化疗益处，也可用作血管性水肿的治疗方法。

Plasma kallikrein-IN-1 is a PKK inhibitor with an IC 50 value of 0.5 nM.

Plasma kallikrein-IN-3, a potent inhibitor ( IC 50 : 0.15 μM) of plasma kallikrein, finds application in research related to hereditary angioedema, diabetic macular edema, and diabetic retinopathy [1].

Kallikrein-IN-1 (Formula A) 是一种激肽释放酶 Kallikrein 抑制剂。

Kallikrein-IN-2 (compound 1) 是一种激肽释放酶 Kallikrein 的抑制剂。

Plasma kallikrein-IN-2 是一个有效的 plasma kallikrein (PKal)抑制剂，IC50值为 0.1 nM。Plasma kallikrein-IN-2 可用于遗传性血管水肿、糖尿病性黄斑水肿、糖尿病视网膜病变的研究。

Kallikrein 5-IN-2 是一种选择性 KallikreinKLK5抑制剂 (pIC50=7.1)。KLK5 抑制可以使表皮脱落正常化并减少相关的炎症和瘙痒。

Avoralstat (BCX4161) 是血浆激肽释放酶(PKK)抑制剂，具有口服活性，可用于遗传性血管性水肿的研究。

Sebetralstat (KVD900) 是一种血浆激肽释放酶抑制剂，可用于代谢性疾病的研究。

SSR-182289A (Free) is a thrombin inhibitor.

ZD-2138是一种有效且具有选择性的5-脂氧合酶（5-LOX）的特异性抑制剂，抑制了过敏原诱导的肺支气管收缩，可减少豚鼠孤立气道的神经诱发性快速激肽能收缩。ZD-2138可用来治疗哮喘疾病。

Gabexate mesylate (FOY) 是一种非抗原的类胰蛋白酶丝氨酸蛋白酶抑制剂。

AEBSF hydrochloride (Pefabloc SC) 是一种丝氨酸蛋白酶的不可逆抑制剂。

Leupeptin is a competitive protease inhibitor produced by actinomycetes. Leupeptin can inhibit cysteine, serine and threonine peptidases. Leupeptin inhibits serine proteinases (trypsin (Ki=3.5 nM), plasmin (Ki= 3.4 nM), porcine kallikrein), and cysteine p

FXIa-IN-15 (Compound (S)-10h) 是一种因子 XIa (FXIa) 和血浆激肽释放酶 (PKa) 的抑制剂，其 IC50 值分别为 0.38 nM 和 59.2 nM。FXIa-IN-15 具备抗凝特性，可以延长 50% 激活部分凝血活酶的时间 (aPTT)，其 EC1.5X 为 0.55 μM。

Bradykinin (acetate) 是一种由激肽释放酶-激肽系统产生的活性肽。它是一种炎症介质，也被认为是多种血管和肾功能的神经介质和调节剂。它由血液中的 kallidin 酶促产生，是一种强大的血管扩张剂，可引起平滑肌收缩，并可能介导炎症。它具有作为人血清代谢物和血管扩张剂的作用。它是缓激肽 (2+) 的互变异构体。

PKSI-527 is an inhibitor of plasma kallikrein (Ki = 0.81 μM). It is selective for plasma kallikrein over glandular kallikrein, plasmin, thrombin, urokinase, and Factor Xa (Kis = >500, 390, >500, 200, and >500 μM, respectively). PKSI-527 reduces bradykinin generation induced by kaolin and λ-carrageenan ex vivo in human plasma. It also prolongs partial thromboplastin and euglobulin clot lysis times. In vivo, PKSI-527 (300 mg/kg per day) reduces hyperplasia, pannus formation, and infiltration of inflammatory cells in the tarsal joint of mice with collagen-induced arthritis.

Berotralstat (BCX7353) is a second-generation, synthetic, and orally active plasma kallikrein inhibitor with low toxicity. It is highly specific and effectively used in the research of hereditary angioedema (HAE) attacks. Berotralstat functions by inhibiting the enzymatic activity of plasma kallikrein, which is responsible for the release of bradykinin. This blocking mechanism targets the major biologic peptide involved in the promotion of swelling and pain associated with HAE attacks[1][2].

pFR-pNA, chromogenic substrate for the determination of plasma kallikrein-like activity. CAS Number (net): 64816-19-9.

Feniralstat (KVD-824) 是一种具有选择性和高效性的激肽释放酶 (kallikrein) 抑制剂，可用于研究免疫系统疾病和心血管疾病。

Leupeptin is a naturally occurring protease inhibitor that can inhibit cysteine, serine and threonine peptidases. Leupeptin is an organic compound produced by actinomycetes. Leupeptin inhibits serine proteinases (trypsin (Ki=3.5 nM), plasmin (Ki= 3.4 nM), porcine kallikrein), and cysteine proteinases (papain, cathepsin B (Ki = 4.1 nM), endoproteinase Lys-C). It does not inhibit α-chymotrypsin or thrombin. Leupeptin is a competitive transition state inhibitor and its inhibition may be relieved by an excess of substrate.